RU2542435C2 - Биомаркер для мониторинга пациентов - Google Patents

Биомаркер для мониторинга пациентов Download PDF

Info

Publication number
RU2542435C2
RU2542435C2 RU2011142612/15A RU2011142612A RU2542435C2 RU 2542435 C2 RU2542435 C2 RU 2542435C2 RU 2011142612/15 A RU2011142612/15 A RU 2011142612/15A RU 2011142612 A RU2011142612 A RU 2011142612A RU 2542435 C2 RU2542435 C2 RU 2542435C2
Authority
RU
Russia
Prior art keywords
patient
interferon
accordance
specified
treatment
Prior art date
Application number
RU2011142612/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2011142612A (ru
Inventor
АКРЕ Брюс
МАРИ-БАСТЬЕН Беранжера
Original Assignee
Трансжене Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Трансжене Са filed Critical Трансжене Са
Publication of RU2011142612A publication Critical patent/RU2011142612A/ru
Application granted granted Critical
Publication of RU2542435C2 publication Critical patent/RU2542435C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
RU2011142612/15A 2009-03-24 2010-03-23 Биомаркер для мониторинга пациентов RU2542435C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305256 2009-03-24
EP09305256.1 2009-03-24
PCT/EP2010/053755 WO2010108908A1 (en) 2009-03-24 2010-03-23 Biomarker for monitoring patients

Publications (2)

Publication Number Publication Date
RU2011142612A RU2011142612A (ru) 2013-04-27
RU2542435C2 true RU2542435C2 (ru) 2015-02-20

Family

ID=42153802

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011142612/15A RU2542435C2 (ru) 2009-03-24 2010-03-23 Биомаркер для мониторинга пациентов

Country Status (21)

Country Link
US (1) US20120028279A1 (he)
EP (1) EP2411815B1 (he)
JP (1) JP5774578B2 (he)
KR (1) KR20110138354A (he)
CN (1) CN102362184B (he)
AU (1) AU2010227611B2 (he)
BR (1) BRPI1009892A2 (he)
CA (1) CA2756133A1 (he)
CO (1) CO6450670A2 (he)
DK (1) DK2411815T3 (he)
ES (1) ES2555858T3 (he)
HK (1) HK1161644A1 (he)
HU (1) HUE026194T2 (he)
IL (1) IL214611A (he)
MX (1) MX2011010061A (he)
NZ (1) NZ595290A (he)
RU (1) RU2542435C2 (he)
SG (2) SG2014014021A (he)
TW (1) TWI470225B (he)
WO (1) WO2010108908A1 (he)
ZA (1) ZA201106890B (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028240T2 (en) 2009-07-10 2016-12-28 Transgene Sa Biomarker Patient Selection and Related Procedures
CA2870876C (en) * 2012-05-23 2019-10-01 Genentech, Inc. Selection method for therapeutic agents
EP3129036B1 (en) * 2014-04-11 2021-08-11 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958826A1 (en) * 1997-03-07 1999-11-24 Akira Hayashi Immunotherapeutic agent for cancer containing nucleoidal component of bacterium as active ingredient
US20050164168A1 (en) * 2003-03-28 2005-07-28 Cullum Malford E. Method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JP4475683B2 (ja) 1996-07-25 2010-06-09 アメリカ合衆国 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU6004798A (en) * 1997-02-06 1998-08-26 University College Dublin Electrochromic system
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
JPH10306029A (ja) * 1997-03-07 1998-11-17 Akira Hayashi 細菌の菌体成分を有効成分とする癌免疫療法剤
US20030138454A1 (en) * 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9819726D0 (en) 1998-09-11 1998-11-04 Advanced Environmental Enginee Vapour recovery system
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
AU761567B2 (en) 1999-02-04 2003-06-05 Geron Corporation Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
ES2288488T3 (es) 1999-11-15 2008-01-16 Onyx Pharmaceuticals, Inc. Adenovirus oncoliticos.
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
WO2002076485A2 (en) * 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AU2003241252A1 (en) * 2002-06-06 2003-12-22 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
MXPA06003977A (es) * 2003-10-10 2006-06-27 Powderject Vaccines Inc Metodo.
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
KR20060129013A (ko) * 2004-01-13 2006-12-14 가부시키가이샤 디나벡크 겐큐쇼 면역자극성 사이토카인을 코드하는 마이너스 가닥 ｒｎａ 바이러스 벡터를 사용하는 종양의 유전자 치료
CN101035901A (zh) * 2004-07-22 2007-09-12 细胞基因系统有限公司 腺病毒载体中转基因的插入
US8889142B2 (en) * 2004-10-25 2014-11-18 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
KR101205064B1 (ko) * 2005-04-26 2012-11-27 에자이 알앤드디 매니지먼트 가부시키가이샤 암 면역요법을 위한 조성물과 방법
CA2613327A1 (en) * 2005-06-28 2007-02-08 Biomira, Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
WO2007094027A2 (en) * 2006-02-17 2007-08-23 Paolo La Colla Methods for the diagnosis of proliferative and/or conformational diseases
EP2199793A4 (en) * 2007-09-10 2012-01-11 Riken METHOD FOR EVALUATING HUMAN DENDRITIC CELLS AND IMMUNOTHERAPEUTIC AGENT FOR HUMAN CELLS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958826A1 (en) * 1997-03-07 1999-11-24 Akira Hayashi Immunotherapeutic agent for cancer containing nucleoidal component of bacterium as active ingredient
US20050164168A1 (en) * 2003-03-28 2005-07-28 Cullum Malford E. Method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARAVEYAS A. et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interkukin-2 in peripheral blood lymphocytes.,Annals of Oncology, 1999 Jul;10(7):817-24. Найдено в Интернет [он-лайн], 20.03. 2014 на сайте http://annonc.oxfordjournals.org/content/10/7/817.full.pdf. SEITZ M. et al. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma, Ann Rheum Dis. Aug 1988; 47(8): 642-644. PMCID: PMC1006714. Найдено из Интернета [он-лайн] 25.03.2014 на сайте http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1006714 *

Also Published As

Publication number Publication date
EP2411815B1 (en) 2015-11-11
KR20110138354A (ko) 2011-12-27
SG2014014021A (en) 2014-07-30
TWI470225B (zh) 2015-01-21
AU2010227611B2 (en) 2014-05-29
RU2011142612A (ru) 2013-04-27
CN102362184A (zh) 2012-02-22
SG174507A1 (en) 2011-10-28
EP2411815A1 (en) 2012-02-01
ES2555858T3 (es) 2016-01-11
MX2011010061A (es) 2011-11-18
DK2411815T3 (en) 2015-11-30
CA2756133A1 (en) 2010-09-30
HUE026194T2 (en) 2016-05-30
IL214611A (he) 2015-07-30
US20120028279A1 (en) 2012-02-02
HK1161644A1 (en) 2012-07-27
IL214611A0 (en) 2011-09-27
AU2010227611A1 (en) 2011-08-25
TW201038943A (en) 2010-11-01
JP2012521549A (ja) 2012-09-13
CN102362184B (zh) 2015-04-08
WO2010108908A1 (en) 2010-09-30
JP5774578B2 (ja) 2015-09-09
CO6450670A2 (es) 2012-05-31
NZ595290A (en) 2012-09-28
ZA201106890B (en) 2012-06-27
BRPI1009892A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
RU2552292C2 (ru) Биомаркер для отбора пациентов и связанные с ним способы
RU2542435C2 (ru) Биомаркер для мониторинга пациентов
RU2555340C2 (ru) Биомаркер для мониторинга пациентов
US9207231B2 (en) Biomarker for selecting patients and related methods

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170324